title: Recommend maintenance therapy with lenalidomide in multiple myeloma.
abstract: Thalidomide was the first immunomodulatory drug used as maintenance after autologous stem cell transplant (ASCT) in multiple myeloma (MM). This showed improved progression-free survival (PFS) and in some cases, overall survival (OS). Despite this, use of thalidomide was limited due to toxicity and high rates of therapy discontinuation. Lenalidomide, an analog of thalidomide, had a more favorable toxicity profile making its use in maintenance a potential approach. The use of lenalidomide as a maintenance therapy after ASCT in newly diagnosed MM patients has been investigated in four phase III randomized control studies.
authors.affiliation: Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX. Electronic address: eemanasanch@mdanderson.org.
authors.forename: Elisabet E
authors.initials: EE
authors.lastname: Manasanch
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014182:Transplantation, Autologous
chemical_list: D013792:Thalidomide; D000077269:Lenalidomide
keywords: Lenalidomide; Maintenance; Myeloma; Transplant